Stay updated on Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 has been added to the page. The government funding status warning banner about potential outages has been removed.SummaryDifference0.5%

- Check21 days agoChange DetectedA government funding status notice was added indicating the NIH Clinical Center is open and updates can be found at external sites. The page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check28 days agoChange DetectedUI and data metadata changes include adding a glossary display option and updating labels such as 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', while removing the previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision history updated to v3.3.4, replacing v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded a Locations section listing Pennsylvania and Texas as study sites, replacing the former Pennsylvania Locations and Texas Locations entries.SummaryDifference0.4%

- Check85 days agoChange DetectedThe page now displays a new revision label, v3.3.2, replacing v3.3.1, indicating a minor update to the study record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.